Phathom Pharmaceuticals (PHAT)

• Market cap: $928M
• 1 day: -1.81%
• 5 days: -9.63%
• 1 month: 12.32%
• 3 months: 50.23%
• 6 months: 443.33%
• Year to date: 77.9%
• 1 year: -27.56%
• 5 years: -68.75%
• 10 years: -46.99%
• Sector: Healthcare
• Industry: Biotechnology

About: Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.

Employees: 427